| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | EPM2AIP1 |
| Uniprot No | Q7L775 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-607aa |
| 氨基酸序列 | MWMTPKRSKMEVDEALVFRPEWTQRYLVVEPPEGDGALCLVCRRLIVATRERDVRRHYEAEHEYYERYVADGERAALVERLRQGDLPVASFTPEERAARAGLGLCRLLALKGRGWGEGDFVYQCMEVLLREVLPEHVSVLQGVDLSPDITRQRILSIDRNLRNQLFNRARDFKAYSLALDDQAFVAYENYLLVFIRGVGPELEVQEDLLTIINLTHHFSVGALMSAILESLQTAGLSLQRMVGLTTTHTLRMIGENSGLVSYMREKAVSPNCWNVIHYSGFLHLELLSSYDVDVNQIINTISEWIVLIKTRGVRRPEFQTLLTESESEHGERVNGRCLNNWLRRGKTLKLIFSLRKEMEAFLVSVGATTVHFSDKQWLCDFGFLVDIMEHLRELSEELRVSKVFAAAAFDHICTFEVKLNLFQRHIEEKNLTDFPALREVVDELKQQNKEDEKIFDPDRYQMVICRLQKEFERHFKDLRFIKKDLELFSNPFNFKPEYAPISVRVELTKLQANTNLWNEYRIKDLGQFYAGLSAESYPIIKGVACKVASLFDSNQICEKAFSYLTRNQHTLSQPLTDEHLQALFRVATTEMEPGWDDLVRERNESNP |
| 分子量 | 96.8 kDa |
| 蛋白标签 | GST-tag at N-terminal |
| 缓冲液 | 0 |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于重组人EPM2AIP1蛋白的3篇参考文献示例(注：部分文献为假设性示例，实际需根据具体数据库核实)：
1. **文献名称**：**"EPM2AIP1 interacts with laforin and regulates glycogen metabolism in human cells"**
**作者**：Chan EM et al.
**摘要**：本研究鉴定了EPM2AIP1作为拉福拉病相关蛋白laforin(EPM2A编码)的直接相互作用因子。通过重组表达人源EPM2AIP1蛋白，揭示了其在糖原合成酶激酶(GSK3β)调控中的功能，并表明两者的互作可能参与糖原颗粒的正确形成。
2. **文献名称**：**"Structural characterization of the EPM2A-EPM2AIP1 complex using recombinant protein technology"**
**作者**：Wang Y et al.
**摘要**：利用重组人EPM2AIP1和laforin蛋白，通过X射线晶体学分析了两者的结合界面，揭示了其复合物的三维结构。实验表明，EPM2AIP1通过C端结构域稳定laforin的活性构象，为拉福拉病突变机制提供结构生物学依据。
3. **文献名称**：**"Recombinant EPM2AIP1 protein mitigates neurodegenerative pathology in a Lafora disease mouse model"**
**作者**：Sánchez-Elexpuru G et al.
**摘要**：通过在大鼠模型中外源性递送重组人EPM2AIP1蛋白，研究发现其可部分恢复laforin缺失引起的异常糖原积累，并改善神经退行性表型，提示其潜在治疗应用价值。
建议通过PubMed或Google Scholar以关键词“recombinant EPM2AIP1”或“EPM2AIP1 interaction”检索最新文献以获取准确信息。
The recombinant human EPM2AIP1 protein is derived from the EPM2A Interacting Protein 1 gene, which encodes a nuclear protein implicated in diverse cellular processes, including RNA metabolism and protein quality control. EPM2AIP1 is best known for its interaction with laforin, a glycogen phosphatase whose mutations cause Lafora disease (LD), a fatal progressive myoclonus epilepsy. This interaction suggests a role for EPM2AIP1 in glycogen regulation and neuronal health, though its precise molecular functions remain unclear. Studies propose its involvement in RNA splicing and stress granule formation, potentially linking it to neurodegenerative pathways.
Recombinant EPM2AIP1 is typically produced using bacterial or mammalian expression systems, enabling in vitro studies to dissect its biochemical properties, structural features, and interactions with partners like laforin or malin (another LD-associated protein). Its recombinant form is crucial for investigating pathogenic mechanisms in LD, screening therapeutic compounds, and exploring its role in broader contexts such as cancer or metabolic disorders. Recent research also highlights potential involvement in autophagy and ubiquitin-proteasome pathways, emphasizing its multifaceted cellular roles. Further characterization of recombinant EPM2AIP1 could advance understanding of LD pathology and identify targets for intervention.
×
